Because of its recent FDA approval for the treatment of children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and tolerability in that population (34, 35), leniolisib was tested for its ability to block BMPR2 loss-induced AKT activation. The gene discussed is AKT1; the disease is activated PI3K-delta syndrome.